Clinical trial · Interventional
Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer
A Phase I Study of Immunization With Alternating Human Papillomavirus E7 Lipopeptide Epitope Vaccine and Dendritic Cells Presenting the E7 Epitope for the Treatment of Recurrent or Persistent Cervical Cancer
NCT00003977CI-TRIAL-00002018completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients with recurrent or persistent cervical cancer that cannot be treated with surgery or radiation therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| human papillomavirus 16 E7 peptide | Biological | — | UNRESOLVED |
| in vitro-treated peripheral blood stem cell transplantation | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven recurrent or persistent cervical cancer not amenable to surgery or radiotherapy * Measurable and evaluable disease * HLA-A2 positive PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * More than 3 months Hematopoietic: * WBC greater than 3,000/mm\^3 * Platelet count greater than 100,000/mm\^3 * Hemoglobin greater than 8.0 g/dL * No coagulation disorders Hepatic: * Bilirubin less than 2.0 mg/dL * SGOT less than 4 times upper limit of normal Renal: * Creatinine less than 1.5 mg/dL OR * Creatinine clearance greater than 75 mL/min Cardiovascular: * No major cardiovascular illness Pulmonary: * No major pulmonary illness Other: * HIV negative * Hepatitis B surface antigen negative * No active systemic infection * Not pregnant * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * At least one month since prior biologic therapy Chemotherapy: * At least one month since prior chemotherapy Endocrine therapy: * At least one month since prior endocrine therapy * No concurrent steroid therapy Radiotherapy: * See Disease Characteristics * At least one month since prior radiotherapy Surgery: * See Disease Characteristics * At least one month since prior surgery
References
Publications (0)
Data not yet available
No reference posted for this study.